|

Decitabine Clinical Trials

29 actively recruiting trials across 14 locations

▼ -2 trials since June 2026

Also known as: 127716, 2''-Deoxy-5-azacytidine, 5-Aza-2''-deoxycytidine, 5-Aza-2'-deoxycytidine, 5-aza-2'-deoxycytydine +6 more

Pipeline

Early 1: 1Phase 1: 7Phase 2: 13Phase 3: 1Phase 1/2: 6Phase 2/3: 1

Top Sponsors

M.D. Anderson Cancer Center6
University of Washington2
Montefiore Medical Center2
Mayo Clinic2
H. Lee Moffitt Cancer Center and Research Institute2

Indications

Cancer29
Acute Myeloid Leukemia13
Recurrent Acute Myeloid Leukemia4
Myelodysplastic Syndromes4
Myeloid Malignancies3

Houston, Texas6 trials

A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)

MD Anderson Cancer Center

Phase 2

A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies

The University of Texas M. D. Anderson Cancer Center

Phase 1/2

Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

University of Texas MD Anderson Cancer Center

Phase 2

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

M D Anderson Cancer Center

Phase 2

Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies

MD Anderson Cancer Center

Phase 1/2

Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

M D Anderson Cancer Center

Phase 1/2

Other5 trials

Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies

Phase 1/2

Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT

Phase 2/3

Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

Phase 2

HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML

Phase 3

Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML

Phase 2

Seattle, Washington3 trials

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

Fred Hutch/University of Washington Cancer Consortium

Phase 1/2

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Birmingham, Alabama2 trials

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

Children's Hospital of Alabama

Phase 1

Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

University of Alabama at Birmingham

Phase 1

Boston, Massachusetts2 trials

A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies

Boston Children's Hospital

Phase 2

Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML

Beth Israel Deaconess Medical Center

Phase 1

Cleveland, Ohio2 trials

5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies

Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center

Early 1

Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant

Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center

Phase 1/2

Phoenix, Arizona1 trial

Avapritinib With Decitabine in Patients With SM-AHN

Mayo Clinic - Arizona

Phase 1

Clovis, California1 trial

Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure

UCSF-Fresno

Phase 2

Sacramento, California1 trial

Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML

University of California Davis Health (UC Davis Health)

Phase 2

Jacksonville, Florida1 trial

Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer

Mayo Clinic in Florida

Phase 1

Tampa, Florida1 trial

Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD

Moffitt Cancer Center

Phase 2

Maywood, Illinois1 trial

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

Loyola University Medical Center

Phase 2

Iowa City, Iowa1 trial

High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)

University of Iowa Health Care

Phase 1

Mankato, Minnesota1 trial

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Mayo Clinic Health Systems-Mankato

Phase 2

The Bronx, New York1 trial

FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia

Montefiore Medical Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.